The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
82
Artesia Clinical Site - Site 02
Artesia, California, United States
Inglewood Clinical Site - Site 03
Inglewood, California, United States
Petaluma Clinical Site - Site 05
Petaluma, California, United States
New Haven Clinical Site - Site 01
New Haven, Connecticut, United States
intraocular pressure change from baseline.
Time frame: 4 weeks
Adverse events as a measure of safety/tolerability
Time frame: 4 weeks
IOP assessments at weekly visits
Time frame: Weeks 1, 2, 3, 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Atlanta Clinical Site - Site 04
Atlanta, Georgia, United States
High Point Clinical Site - Site 06
High Point, North Carolina, United States